Preliminary data published in June 2023 also suggests that GLP-1 drugs 'could modulate crucial pathways in the pathogenesis of inflammatory bowel disease (IBD), such as chronic inflammation circuits, intestinal tight junctions, and gut microbiome dysbiosis, setting the stage for human trials to investigate the role of these agents in the treatment of IBD among people with or without diabetes and obesity' (Arvanitakis, Theocharis, Popovic
Is this for diabetes, metabolic health, weight management, or another medical reason
GHK-Cu research benefits from consistent subcutaneous delivery
It is no surprise that growth hormones are an essential part of human development, but as people age, their growth hormone levels decline, and so do things such as muscle growth, metabolism, brain function, energy production, and much more
Pinto, an obesity and family medicine doctor at Johns Hopkins Medicine in Baltimore, who wasnt involved in the research